These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Do mTOR inhibitors still have a future in ADPKD? Perico N; Remuzzi G Nat Rev Nephrol; 2010 Dec; 6(12):696-8. PubMed ID: 21109768 [No Abstract] [Full Text] [Related]
8. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment. Ponticelli C; Locatelli F Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121 [No Abstract] [Full Text] [Related]
9. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials. He Q; Lin C; Ji S; Chen J Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868 [TBL] [Abstract][Full Text] [Related]
17. Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis. Lin CH; Chao CT; Wu MY; Lo WC; Lin TC; Wu MS Int Urol Nephrol; 2019 Nov; 51(11):2015-2025. PubMed ID: 31578673 [TBL] [Abstract][Full Text] [Related]
18. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial. Riegersperger M; Herkner H; Sunder-Plassmann G Trials; 2015 Apr; 16():182. PubMed ID: 25899445 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708 [TBL] [Abstract][Full Text] [Related]
20. Randomized intervention studies in human polycystic kidney and liver disease. Schrier RW J Am Soc Nephrol; 2010 Jun; 21(6):891-3. PubMed ID: 20431043 [No Abstract] [Full Text] [Related] [Next] [New Search]